摘要
目的观察半剂量依那西普联合甲氨蝶呤治疗强直性脊柱炎(AS)髋关节病变的疗效。方法对25例伴单侧或双侧髋关节受累的AS患者给予半剂量依那西普25 mg,皮下注射,每周1次,持续12周,并联合甲氨蝶呤15 mg,口服或皮下注射,每周1次。观察参数包括治疗前后的Harris髋关节评分、AS疾病活动度评分(ASDAS)和Bath AS髋关节X线指数(BASRI-hip)。结果 25例患者中共33个髋关节受累,其治疗前Harris髋关节评分为(50.79±14.52)分,治疗12周后评分明显上升为(79.97±15.54)分(P<0.01);治疗前ASDAS评分为(4.76±0.69)分,治疗12周后明显下降为(2.62±0.50)分(P<0.01);而BASRI-hip治疗前后无明显改变。本研究治疗和随访过程中患者未出现结核和其他严重感染。结论半剂量依那西普联合甲氨蝶呤治疗AS相关髋关节病变有效,未见明显不良反应。
Objective To observe the therapeutic effect of half-value dose Etanercept combined with Methoterxate （MTX） in hip joint lesion of ankylosing spondylitis （AS）. Methods Twenty-five patients with AS with unilateral or bilateral hip joint lesion were enrolled in the study. These patients received Etanereept 25 mg injected subcutaneously once a week for 12 weeks, combined with MTX 15 mg once a week administrated orally or subcutaneously. Parameters observed included Har- ris hip score, ankylosing spondylitis disease activity score （ASDAS）, Bath ankylosing spondylitis radiologic index-hip（BAS- RI-hip） before and after the treatment. Results Thirty-three hip joints were enrolled in 25 patients. Harris hip score were elevated significantly from （50.79±14.52） before treatment to （79.97±15.54） after treatment （P 〈 0.01） while ASDAS declined from （4.76±0.69） to （2.62±0.50）（P 〈 0.01）. But there was no change in BASRI-hip before and after treatment. During the treatment and follow-up period, no tuberculosis or severe infection was observed. Conclusion Half-value dose Etanercept combined with Methotrexate is effective in treating hip joint lesion of AS without serious side effects.
出处
《中国现代医生》
2012年第18期69-71,共3页
China Modern Doctor
关键词
强直性脊柱炎
髋关节病变
依那西普
半剂量
Ankylosing spondylitis
Hip joint lesion
Etanercept
Half-value dose
